Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lisziewicz

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Vaccine|February 9, 2011
Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trialL Gudmundsdotter, B Wahren, B K Haller, et al.
AIDS Research and Human Retroviruses|November 14, 1997
Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistanceF Lori, A G Malykh, A Foli, et al.
Gene Therapy|April 4, 2014
Exploitation of Langerhans cells for in vivo DNA vaccine delivery into the lymph nodesE R Tőke, O Lőrincz, Z Csiszovszki, et al.
Nature Medicine|May 6, 1999
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapyD Finzi, J Blankson, J D Siliciano, et al.
AIDS Research and Human Retroviruses|June 10, 2005
Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potencyFranco Lori, R B Pollard, L Whitman, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Vaccine|February 9, 2011
Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trialL Gudmundsdotter, B Wahren, B K Haller, et al.
AIDS Research and Human Retroviruses|November 14, 1997
Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistanceF Lori, A G Malykh, A Foli, et al.
Gene Therapy|April 4, 2014
Exploitation of Langerhans cells for in vivo DNA vaccine delivery into the lymph nodesE R Tőke, O Lőrincz, Z Csiszovszki, et al.
Nature Medicine|May 6, 1999
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapyD Finzi, J Blankson, J D Siliciano, et al.
AIDS Research and Human Retroviruses|June 10, 2005
Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potencyFranco Lori, R B Pollard, L Whitman, et al.
Pageof 6